Clinical trial of a monophasic estroprogestin oral formulation containing 20 μg ethinyl estradiol and 75 μg gestodene

Gynecological Endocrinology

Volumn 15, Issue 4, 2001, Pages 265-271

  Lello, S ^a   Monterubbianesi, M ^b   Guardianelli, F ^a   Bianchi, C ^b   Simonelli, C ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Body weight; Combined estroprogestin oral formulation; Ethinyl estradiol; Gestodene; Sexuality; Third generation progestogen

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL PLUS GESTODENE; GESTAGEN;

ADULT; AMENORRHEA; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUAL FUNCTION;

EID: 0034847351     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/713602883     Document Type: Article

References (9)

1. Progestogens: Pharmacological characteristics and clinically relevant differences
2. Pharmacokinetics of oestrogens and progestogens
3. Pharmacokinetics and metabolism of progestins in humans
4. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations
5. Treatment of diminished sexual response associated with the use of oral contraceptives
6. Oral contraception and sexuality
7. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premestrual symptoms